Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Bullboard Posts
Comment by 2b7f6fabon Apr 17, 2018 9:19pm
133 Views
Post# 27901911

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Optimized Treatment

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Optimized TreatmentI'm not following you there, how do you get a sicker pool of patients if you exclude those with known UUTUC?  ...
Just wondering what if any contract between UHN/PMC and TLT there exists.  Wondering here if UHN/PMC treated patients that were outside the protocols of the trial design.  If yes, has TLT suffered damages.


Macer wrote: Just sayin
By narrowing down the selection pool of patients with the exclusion criteria they would automatically end up with a higher percentage of sicker patients. It would then not be ethical to select only the best of the sickest and turn the others away. Medicine is often more complex than it seems.

Bottom line, when they design phase 2 and get approval the results will be highly sought after and watched closely.

Throw in a couple of phase 1 trials for other indications and there will be a pipeline in the making.

Macer


Bullboard Posts